List of publications


BETPSY Project


Biomarkers in autoimmune EncephaliTis and

Paraneoplastic neurological SYndromes



Scientific articles 

Khatib L., and al. Autoimmune Cerebellar Ataxia Associated withAnti‑Glutamate Receptor δ2 Antibodies: a Rare but Treatable Entity. The Cerebellum. 2023 (WP2)


Farina A., and al. Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors. Neurol Neuroimmunol Neuroinflamm. 2023DOI: (WP2)


Vabanesi M., and al. SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques. Journal of neurology. 202310.1007/s00415-022-11523-y (WP2)


Benoit J, and al. Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis Clues for Diagnosis. Neurol Neuroimmunol Neuroinflamm. 2022 (WP2)


Moritz C, and al. Conformation-stabilizing ELISA and cell-based assays reveal patient subgroups targeting three different epitopes of AGO1 antibodies. Front. Immunol. 2022 (WP2)


Flet-Berliac L, and al. Long-term outcome of paediatric anti-N-methyl-D-aspartate receptor encephalitis. Dev Med Child Neurol. 2022 (WP2)


Villagran-Garcia M and al. Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review. J Neurol. 2022. doi: 10.1007/s00415-022-11356-9 (WP2)


Peter E, Do LD, and al. Cerebellar Ataxia With Anti-DNER Antibodies: Outcomes and Immunologic Features. Neurol Neuroimmunol Neuroinflamm. 2022doi: 10.1212/NXI.0000000000200018 (WP2)


Peter E, Treilleux I, and al. Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration. Neurol Neuroimmunol Neuroinflamm. 2022. 10.1212/NXI.0000000000200015 (WP4)


Peris Sempre V, Muñiz-Castrillo S, and al. Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2022. DOI: (WP3)

Lardeux P, and al. Core cerebrospinal fuid biomarker profile in anti‑LGI1 encephalitisJournal of neurology. 2022. (WP2)

Tholance Y, Antoine JC, and al. Anti-FGFR3 antibody epitopes are functional sites and correlate with the neuropathy patternJournal of neuroimmunology. 2021. (WP2)

Vogrig A, Péricart S, and al. Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitisBrain Communications. 2021. (WP2)

Do L, Moritz C, and al. Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic DiseasesNeurol Neuroimmunol Neuroinflamm. 2021. DOI: (WP2)

Muñiz-Castrillo S, Hedou J, and al. Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis. Brain, 2021; awab153, (WP3)

Muñiz‑Castrillo S, Haesebaert J and al. Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis. Neurol Neuroimmunol Neuroinflamm. 2021. DOI: (WP3)

Muñiz‑Castrillo S, Vogrig A and al. Familial autoimmunity in neurological patients with GAD65 antibodies: an interview-based study. Journal of neurology. 2021. (WP3)

Moritz C, and al. CIDP Antibodies Target Junction Proteins and Identify Patient Subgroups. Neurol Neuroimmunol Neuroinflamm. 2021. (WP2)

Vogrig A, and al. Cranial Nerve Disorders Associated with Immune Checkpoint Inhibitors. Neurology. 2020. (WP2)

Moritz C and al. Proper definition of the set of autoantibody-targeted antigens relies on appropriate reference group selection. New biotechnology. 2020. (WP2)

Hébert J, Riche B and al. Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm. 2020; 7 (6). (WP1-WP6)

Muñiz‑Castrillo S, Joubert B, and al. Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features. J Neurol Neurosurg Psychiatry. 2020; 0:1–9. (WP3)


Muñiz‑Castrillo S, Vogrig A, Joubert B, and al. Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies. Cerebellum. 2020; 19 715-721. (WP2)


Vogrig A, Muñiz‑Castrillo S, Joubert B, and al. Central nervous system complications associated with immune checkpoint inhibitors. J Neurol Neurosurg Psychiatry. 2020; . doi: 10.1136/jnnp-2020-323212 (WP2)


Simard C, Vogrig A, Joubert B, and al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm. 2020; 7:e699. DOI: (WP2)


Déchelotte B, Muñiz‑Castrillo S, Joubert B, and al. Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurological syndromes. Neurol Neuroimmunol Neuroinflamm. 2020; 7(3):e701. (WP2)


Muñiz‑Castrillo S, Ambati A, Dubois V, and al. Primary DQ effect in the association between HLA and neurological syndromes with anti-GAD65 antibodies. J Neurol. 2020; 267:1906-1911. (WP3)


Vogrig. A, Gigli, G.L., Segatti, S. and al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol. 2020; 267: 26-35 (WP2)


Joubert, B., Belbezier, A., Haesebaert, J. and al. Long-term outcomes in temporal lobe epilepsy with glutamate decarboxylase antibodies. J Neurology. 2020. (WP2)




Campérat L and al. Autoimmune neuromyotonia. Curr Opin Neurol. 2022. 10.1097/WCO.0000000000001104. (WP2)


Antoine JC. Sensory neuronopathies, diagnostic criteria and causes. Curr Opin Neurol. 2022. Volume 4, Issue 4, 2022, fcac196, 10.1097/WCO.0000000000001105. (WP2)


Ciano-Petersen NL and al. Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis. Brain communications. 2022. Volume 4, Issue 4, 2022, fcac196, (WP2)


Vaišvilas M, Ciano-Petersen NL, and al. Paraneoplastic encephalitis: clinically based approach on diagnosis and management. Postgrad Med J. 2022 -141766doi: 10.1136/postgradmedj-2022-141766 (WP2)


Muñiz‑Castrillo S, Vogrig A, and al. Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of ProgressesThe Cerebellum. 2022. (WP2)

Ciano-Petersen N, Muñiz‑Castrillo S, and al. Immunomodulation in the acute phase of autoimmune encephalitisRevue neurologique. 2022. (WP2)


Ciano-Petersen N and al. Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Int J Mol Sci. 2021. doi: 10.3390/ijms222313127 (WP2)

Binks S, Uy C, Honnorat J, Irani S. Paraneoplastic neurological syndromes: a practical approach to diagnosis and management. Pract Neurol. 2021 (WP2)


Graus F, Vogrig A, Muñiz-Castrillo S, and al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021. DOI: 10.1212/NXI.0000000000001014 (WP2)


Vogrig A, Muñiz-Castrillo S, and al. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an updateJournal of neurology. 2021. (WP2)


Fels E, Muñiz‑Castrillo S, and al. Role of LGI1 protein in synaptic transmission: From physiology to pathologyNeurobiology of disease. 2021. doi: 10.1016/j.nbd.2021.105537 (WP2)


Wiendl H, Gross C, and al. Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseasesA Systematic Review. Nature Reviews Neurology 2021. (WP5)


Marini A, Bernardini A, and al. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic ReviewNeurology 2021. DOI: (WP2)


Mitoma H, Honnorat J and al. Fundamental Mechanisms of Autoantibody-Induced Impairments on Ion Channels and Synapses in Immune-Mediated Cerebellar Ataxias. Int. J. Mol. Sci. 2020, 21, 4936https://doi:10.3390/ijms21144936 (WP2)


Muñiz-Castrillo S, and al. Diagnostic des encéphalites auto-immunes. Pratique Neurologique – FMC 2020. (WP2) 


Vogrig A, Muñiz‑Castrillo S, Desestret V. Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors. Ther Adv Neurol Disord. 2020; 13:1-15 (WP2)


Yshii L, Bost C, Liblau R. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications. Frontiers in immunology. 2020; 11:911 (WP5)


Muñiz‑Castrillo S, Vogrig A, Honnorat J. Associations between HLA and autoimmune neurological diseases with autoantibodies. Autoimmun Highlights. 2020; 11:2. (WP3)




Mongay-Ochoa N, Vogrig A, Muñiz‑Castrillo S, Honnorat J. Anti‑Hu‑associated paraneoplastic syndromes triggered by immune‑checkpoint inhibitor treatment. J Neurol. 2020 (WP2)


Vogrig A, Muñiz‑Castrillo S, Honnorat J. Value of onconeural antibodies in checkpoint inhibitor-related toxicities. Ann Neurol. 2020. (WP2)




Quero K, Joubert B, et al. Paraneoplastic cerebellar degeneration associated with Hodgkin Lymphoma: A french retrospective cohort. Abstract EP1140. 25th congress of European Hematology Association (EHA). 2020